Prakoeswa Cita Rosita Sigit, Huda Berliana Kurniawati Nur, Indrawati Ditya, Umborowati Menul Ayu, Anggraeni Sylvia, Murtiastutik Dwi, Kerob Delphine
Department of Dermatology, Venereology and Aesthetic, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
Department of Dermatology, Venereology and Aesthetic, Faculty of Medicine Universitas Airlangga, Surabaya, Indonesia.
J Cosmet Dermatol. 2025 Feb;24(2):e70051. doi: 10.1111/jocd.70051.
Atopic dermatitis (AD) poses a challenge due to its chronic inflammatory nature. Recent research highlights microbiome dysbiosis as a key contributor. Emollients "plus" are modern moisturizers containing bacterial lysate, improving skin barrier function and reducing Staphylococcus aureus colonization, thus mitigating AD symptoms. Emollient "plus" containing Vitreoscilla filiformis biomass (Aqua Posae filiformis) is efficient in AD, as single adjunct for milder forms or adjunctive to systemic treatments in more severe forms. Standard recommended moisturizers for AD in Indonesia contain urea 10%.
This trial compared an emollient "plus" (Group A) with urea 10% moisturizer (Group B) in the treatment of mild-to-moderate AD.
PATIENTS/METHODS: Sixty subjects with mild-to-moderate AD were randomized into Groups A and B (30 subjects/group). Test products were applied twice daily for 12 weeks. Clinical and instrumental endpoints assessed at Weeks 0, 4, 8, and 12 included Severity Scoring of AD (SCORAD), Pruritus Visual Analog Scale (PVAS), Eczema Area and Severity Index (EASI), Dermatology Life Quality Index (DLQI), Transepidermal Water Loss (TEWL), skin hydration, skin pH, as well as tolerance evaluation.
Significant differences in favor of the emollient "plus" versus urea 10% were observed on TEWL and skin pH values at Weeks 4, 8, and 12, on SCORAD and skin hydration values at Weeks 8 and 12. EASI, DLQI, and PVAS values differed significantly at Week 12 in favor of Group A. Both products were well tolerated.
This emollient "plus" has superior efficacy in improving AD symptoms and skin barrier function compared to urea 10% moisturizer.
特应性皮炎（AD）因其慢性炎症性质而构成挑战。近期研究强调微生物群失调是一个关键因素。润肤“加”产品是含有细菌裂解物的现代保湿剂，可改善皮肤屏障功能并减少金黄色葡萄球菌定植，从而减轻AD症状。含有丝状透明颤菌生物量（丝状水栖波状菌）的润肤“加”产品对AD有效，可作为较轻形式的单一辅助治疗或更严重形式全身治疗的辅助治疗。印度尼西亚AD的标准推荐保湿剂含有10%的尿素。
本试验比较了一种润肤“加”产品（A组）与含10%尿素的保湿剂（B组）治疗轻至中度AD的效果。
患者/方法：60例轻至中度AD患者被随机分为A组和B组（每组30例）。试验产品每天涂抹两次，持续12周。在第0、4、8和12周评估的临床和仪器终点包括AD严重程度评分（SCORAD）、瘙痒视觉模拟量表（PVAS）、湿疹面积和严重程度指数（EASI）、皮肤病生活质量指数（DLQI）、经表皮水分流失（TEWL）、皮肤水合作用、皮肤pH值以及耐受性评估。
在第4、8和12周时，润肤“加”产品在TEWL和皮肤pH值方面显著优于含10%尿素的产品；在第8和12周时，在SCORAD和皮肤水合作用值方面也有显著差异。在第12周时，EASI、DLQI和PVAS值有显著差异，A组更优。两种产品耐受性均良好。
与含10%尿素的保湿剂相比，这种润肤“加”产品在改善AD症状和皮肤屏障功能方面具有更高的疗效。
